Erbe D - Search Results

1

Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent.

Artis DR, Lin JJ, Zhang C, Wang W, Mehra U, Perreault M, Erbe D, Krupka HI, England BP, Arnold J, Plotnikov AN, Marimuthu A, Nguyen H, Will S, Signaevsky M, Kral J, Cantwell J, Settachatgull C, Yan DS, Fong D, Oh A, Shi S, Womack P, Powell B, Habets G, West BL, Zhang KY, Milburn MV, Vlasuk GP, Hirth KP, Nolop K, Bollag G, Ibrahim PN, Tobin JF. Artis DR, et al. Among authors: erbe d. Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):262-7. doi: 10.1073/pnas.0811325106. Epub 2008 Dec 30. Proc Natl Acad Sci U S A. 2009. PMID: 19116277 Free PMC article.

2

Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists.

Erbe DV, Gartrell K, Zhang YL, Suri V, Kirincich SJ, Will S, Perreault M, Wang S, Tobin JF. Erbe DV, et al. Vascul Pharmacol. 2006 Sep;45(3):154-62. doi: 10.1016/j.vph.2006.05.002. Epub 2006 May 16. Vascul Pharmacol. 2006. PMID: 16765099

3

PPARdelta Agonism for the Treatment of Obesity and Associated Disorders: Challenges and Opportunities.

Perreault M, Erbe DV, Tobin JF. Perreault M, et al. PPAR Res. 2008;2008:125387. doi: 10.1155/2008/125387. Epub 2008 Oct 29. PPAR Res. 2008. PMID: 18989368 Free PMC article.

4

Modulation of nutrient sensing nuclear hormone receptors promotes weight loss through appetite suppression in mice.

Perreault M, Will S, Panza D, Gareski T, Harding K, Kubasiak D, Jalenak M, Gartrell K, Wang S, Bollag G, Artis DR, Ibrahim PN, Womack P, Lin JJ, Saiah E, Mansour TS, Vlasuk GP, Erbe DV, Tobin JF. Perreault M, et al. Among authors: erbe dv. Diabetes Obes Metab. 2010 Mar;12(3):234-45. doi: 10.1111/j.1463-1326.2009.01157.x. Diabetes Obes Metab. 2010. PMID: 20152000

5

Ertiprotafib improves glycemic control and lowers lipids via multiple mechanisms.

Erbe DV, Wang S, Zhang YL, Harding K, Kung L, Tam M, Stolz L, Xing Y, Furey S, Qadri A, Klaman LD, Tobin JF. Erbe DV, et al. Mol Pharmacol. 2005 Jan;67(1):69-77. doi: 10.1124/mol.104.005553. Epub 2004 Oct 8. Mol Pharmacol. 2005. PMID: 15475571

6

Structure-activity studies of a series of dipyrazolo[3,4-b:3',4'-d]pyridin-3-ones binding to the immune regulatory protein B7.1.

Green NJ, Xiang J, Chen J, Chen L, Davies AM, Erbe D, Tam S, Tobin JF. Green NJ, et al. Among authors: erbe d. Bioorg Med Chem. 2003 Jul 3;11(13):2991-3013. doi: 10.1016/s0968-0896(03)00183-4. Bioorg Med Chem. 2003. PMID: 12788368

7

Antibodies to B7.1 define the GFCC'C" face of the N-terminal domain as critical for co-stimulatory interactions.

Wang S, Veldman GM, Stahl M, Xing Y, Tobin JF, Erbe DV. Wang S, et al. Immunol Lett. 2002 Sep 2;83(2):77-83. doi: 10.1016/s0165-2478(02)00074-3. Immunol Lett. 2002. PMID: 12067755

8

Small molecule ligands define a binding site on the immune regulatory protein B7.1.

Erbe DV, Wang S, Xing Y, Tobin JF. Erbe DV, et al. J Biol Chem. 2002 Mar 1;277(9):7363-8. doi: 10.1074/jbc.M110162200. Epub 2001 Dec 6. J Biol Chem. 2002. PMID: 11741888 Free article.

9

Prodrug delivery of novel PTP1B inhibitors to enhance insulin signalling.

Erbe DV, Klaman LD, Wilson DP, Wan ZK, Kirincich SJ, Will S, Xu X, Kung L, Wang S, Tam S, Lee J, Tobin JF. Erbe DV, et al. Diabetes Obes Metab. 2009 Jun;11(6):579-88. doi: 10.1111/j.1463-1326.2008.01022.x. Epub 2009 Apr 5. Diabetes Obes Metab. 2009. PMID: 19383031

10

Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses.

Stamper CC, Zhang Y, Tobin JF, Erbe DV, Ikemizu S, Davis SJ, Stahl ML, Seehra J, Somers WS, Mosyak L. Stamper CC, et al. Among authors: erbe dv. Nature. 2001 Mar 29;410(6828):608-11. doi: 10.1038/35069118. Nature. 2001. PMID: 11279502

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

37 results

Search Page